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Clinical and laboratory features of 99 patients receiving
long-term amiodarone therapy were analyzed to deter-
mine which individuals may be at a high risk for de-
veloping amiodarone-induced thyroid dysfunction. The
group of 68 men and 31 women was followed up for an
average of 27 months (range 3 to 60). There were no
differences in age, sex, dose of amiodarone, type or se-
verity of underlying heart disease or baselineserum thy-
roxine levels in patients who developed hypothyroidism
(n = 32) or hyperthyroidism (n = 5) or remained eu-
thyroid (n =62). Baselineserum thyrotropin levelswere
statistically higher in patients who became hypothyroid,
but there wasconsiderable overlap with the other patient
groups. Serum reverse triiodothyronine (reverse T3) ,
which has been suggested to be a marker of amiodarone
efficacy, correlated directly with serum thyroxine levels,
and was not an independent variable. There was no
pattern to the time course for development of thyroid
dysfunction, which occurred in 49% of those followed
Amiodarone is an iodinated organic compound with sub-
stantial antiarrhythmic properties (I). There are three major
ways in which it may interfere with normal thyroid hormone
dynamics: it may interfere with peripheral conversion of
thyroxine to triiodothyronine; it may override intrathyroidal
defense mechanisms against iodine excess; it may interfere
with thyroid hormone binding to intracellular receptors.
Amiodarone decreases the conversion of thyroxine to
triiodothyronine (T3) and increases the level of reverse T3
(2-4). It has been suggested that the serum levels of reverse
T3 may be useful as an indicator of amiodarone efficacy
(5,6). Serum levels of reverse T3 were evaluated to deter-
mine whether reverse T3 may be considered an independent
variable to the effects of amiodarone.
Each 200 mg dose of amiodarone contains 75 mg of
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up and developed as early as 1 month or, in one indi-
vidual, as late as after 3 years of amiodarone therapy.
There are few guidelines for replacement therapy
in patients with amiodarone-induced hypothyroidism.
L-thyroxine dosage was adjusted cautiously in these high
risk individuals to achieve serum thyroxine levelswithin
the reference range of euthyroid individuals taking amio-
darone: the mean dosage required was 136p.g/day. Nor-
malization of serum thyrotropin (TSH) would have re-
quired doses of L-thyroxine that were judged to be
excessively high.
Serum cholesterol increased in the entire group dur-
ing the course of amiodarone administration (from 209
[baseline] to 251 mg/dl [at 6 months)) and remained
elevated. This degree of hypercholesterolemia may be
clinically significant, especially in individuals with un-
derlying heart disease. The cause and type of hypercho-
lesterolemia were not determined.
(J Am Coil CardioI1987;9:175-83)
iodine, of which it is estimated that 6 mg may be released
as free iodine (7). In contrast, the normal dietary require-
ment of iodine ranges from 0.2 to 0.8 mg/day (7). The
normal control mechanisms within the thyroid itself that
modulate the rate of thyroid hormone synthesis against changes
in serum iodide (7,8) may not be able to defend against
such a pharmacologic load of iodine. Thyroid dysfunction
has been reported to occur in 2 to 24% of individuals re-
ceiving amiodarone (5,6,9-16). We retrospectively ana-
lyzed our clinical and laboratory findings in a group of 99
patients on long-term amiodarone therapy to determine
whether there are any factors that might be useful in pre-
dicting who may be at risk of developing thyroid dysfunction
and also to develop guidelines for the therapy of the thyroid
dysfunction.
There is evidence that amiodarone may bring about a
state of intracellular hypothyroidism within the myocardium
by interfering with intracellular binding of thyroid hormone
to its receptors (17-22). It has been suggested that this
intracellular hypothyroidism is selective to the myocardium
in that amiodarone may induce clinical signs of hypothy-
roidism such as bradycardia paradoxically in the face of
elevated serum thyroxine concentrations. More recent evi-
0735-1097/87/$3.50
176 ALBERT ET AL.
THYROID DYSFUNCTION IN AMIODARONE THERAPY
JACC Vol. 9, No. I
January 1987:175-83
dence suggests that the inhibition of thyroid hormone may
have a more generalized effect in that desethylamiodarone,
a major metabolite, may also bind in vitro to thyroid hor-
mone receptors in the liver (21) and pituitary (17). We
therefore questioned whether amiodarone might have an-
other possible systemic effect in modulating serum choles-
terol levels as a marker of primary hypothyroidism.
Methods
Study patients. One hundred four consecutive patients
receiving long-term amiodarone therapy were followed up.
All patients had severe complex ventricular or atrial ar-
rhythmias on ambulatory electrocardiographic monitoring
or exercise testing, and were treated with amiodarone to
abolish symptoms or prevent sudden death in those indi-
viduals with findings that suggested an increased risk of
sudden death. All patients either had not responded to or
had a contraindication to conventional antiarrhythmic ther-
apy. The use of amiodarone in these individuals was ap-
proved by the Institutional Review Boards of Belleville Me-
morial Hospital, Belleville, Illinois (December 5, 1979),
and Oliver C. Anderson Hospital, Maryville, Illinois (July
30, 1981).
There were 66 men and 38 women with an average age
of 66 years. The indications for therapy were severe, po-
tentially lethal ventricular or intractable atrial arrhythmias.
The underlying heart disease was coronary artery disease in
67, hypertensive heart disease in 4, rheumatic heart disease
in 9, cardiomyopathy in 13, asymmetric septal hypertrophy
in 2, mitral valve prolapse in 2 and primary arrhythmias in
7. The dose of amiodarone was given at a loading dose of
1,400 mg/day for 7 days followed by a maintenance dose
of 200 mg/day. If the arrhythmia was refractory as assessed
by standard electrocardiography and ambulatory monitoring
or by exercise testing, the loading dose of 1,400 mg/day
was repeated for 5 days and the maintenance dose titrated
upward. The maintenance dose was also adjusted downward
according to adverse side effects, predominantly sympto-
matic bradycardias. The average maintenance dose was 309
mg and ranged from 100 mg every other day to 600 mg/day.
If arrhythmia control could not be maintained, additional
antiarrhythmic agents were added to the amiodarone regi-
men: quinidine in 6, procainamide in 7 and phenytoin in
58 patients. There was clinically significant improvement
in arrhythmia control in 65 of the 95 patients treated for
ventricular arrhythmias; there was improvement but persis-
tence of ventricular arrhythmias in 24, no change in 6 and
worsening in 1.
Follow-up. Patients were followed up initially at monthly
and then 3 month intervals for serum electrolytes, glucose,
liver function tests, thyroid function [thyroxine (T4) , triio-
dothyronine resin uptake (T3RU), thyrotropin (TSH)], cho-
lesterol and triglycerides (obtained after a 14 hour fast),
electrocardiograms and ambulatory arrhythmia monitoring.
All patients were followed up to determine whether any
baseline variables might be used to predict further thyroid
abnormalities; five patients were excluded from analysis
because they were already receiving exogenous thyroid sup-
plementation (one after radioactive iodine therapy for Graves'
disease, one after thyroidectomy for Graves' disease and
three with antecedent hypothyroidism). The subsequent
analysis is based on the results in the remaining 99 indi-
viduals.
A randomly selected subgroup of 32 patients who were
scheduled for routine follow-up in the fourth quarter of 1982
and first quarter of 1983 were evaluated with T4, T3 resin
uptake, TSH, triiodothyronine by radioimmunoassay, re-
verse triiodothyronine (reverse T3) and had a thyrotropin-
releasing hormone (TRH) stimulation test (500 ]Lg of TRH
given intravenously) (23,24). The thyrotropin (TSH) deter-
minations for the TRH test were all performed in one clinical
laboratory with a reference range of 0 to 6 ]LID/m!. The
initial assay of TSH was begun in 1979 with a less sensitive
assay with a range of 0 to 10 ]LID/m!.
Statistical analysis. Data were analyzed using paired
and unpaired t tests, using the correction of Bonferroni
inequality for multiple assessments. One way analysis of
variance (25), and contingency table analysis were per-
formed on a Hewlett-Packard 97 calculator. Data from the
cholesterol and TSH determinations were first normalized
by log-transformation and analysis performed on geometric
means. Life table analysis was performed as described by
Colton (26).
Results
Incidence of thyroid dysfunction. Ninety-nine consec-
utive patients treated with amiodarone were followed up for
a mean of 27 ± 16 (SD) months (range 3 to 60). All were
euthyroid on initial presentation; five patients with anteced-
ent hypothyroidism had been previously excluded. During
this period of observation 32 patients developed hypothy-
roidism, manifested by clinical signs and symptoms of hypo-
thyroidism such as bradycardia and weight gain, plus a
serum thyroxine (T4) level less than the lower limits of the
reference range of serum thyroxine (T4) (4.5 ]Lg/dl) and
thyrotropin (TSH) greater than 20 ]LID/m!. Five patients
developed hyperthyroidism with the clinical symptoms of
tremor and anxiety, and a serum T4 greater than the upper
limits of the reference range of T4 (see later), with appro-
priate elevations in T3 resin uptake (T3RU) and a TSH that
was low or at the lower level of detection of the TSH assay.
Sixty-two individuals remained euthyroid.
Baseline clinical data on all subjects are shown in Table
1. No baseline clinical variables such as age, sex, type of
underlying heart disease or severity of arrhythmias proved
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Table 1. Baseline Clinical Features in Relation to Outcome of Thyroid Hormone Status During
the Interval of Follow-up
Hypothyroid Hyperthyroid Euthyroid
No. of patients 32 5 62
Male* 19 5 40
Female* 13 0 22
Age (yr ± SO)t 68 ± 7 58 ± II 65 ± II
Heart disease diagnosis]
Coronary artery disease 19 3 42
Hypertensive 3 0 0
Rheumatic 4 0 5
Cardiomyopathy 4 2 7
Asymmetric septal hypertrophy I 0 I
Mitral valve prolapse 0 0 I
Primary arrhythmia I 0 6
Maintenance dose
Amiodarone (mg/day ± SO)§ 325 ± 160 440 ± 167 284 ± 142
Phenytoin (no. of patientsj] 20 2 36
Comparisons among the hypothyroid, hyperthyroid and euthyroid groups: *idC = 3.12; P NS;
tF,."" = 2.38; P = NS; tX'df12 = 12.26; P = NS; §F,."4 = 2.96; P = 0.06; IIx'd'" = 1.86; P = NS.
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useful as a predictor of subsequent thyroid dysfunction.
There was a trend (p = 0.06) toward development of thyroid
dysfunction in individuals receiving higher maintenance doses
of amiodarone (Table I) which did not reach statistical sig-
nificance (at a power of 0.82). There was considerable over-
lap in the dose of amiodarone, and the actual maintenance
dose was not helpful in predicting the outcome of thyroid
dysfunction. There was no significant difference in the de-
gree of arrhythmia control in patients who developed thyroid
dysfunction compared with those who remained euthyroid
(not shown). There were no significant associations with
the use of other medications (digoxin, diuretic drugs, an-
tihypertensive medications or antiariginal medications). Many
of these individuals were also receiving phenytoin, which
is known to have multiple effects on thyroid hormone dy-
namics (27-29), and may also interact with amiodarone
(30). Of the 58 patients receiving phenytoin, 20 became
hypothyroid and 2 became hyperthyroid. Contingency table
analysis did not demonstrate a difference in the outcome of
thyroid dysfunction in patients receiving phenytoin when
compared with those not receiving phenytoin (Table I).
Laboratory data (Table 2). There was no difference in
baseline values of T4 between those who remained euthyroid
and those who developed thyroid dysfunction. There was a
statistically significant elevation of TSH levels at baseline
in those who bec,ame hypothyroid (5.6 versus 3.9 /LIU/ml
for euthyroid individuals; there was a considerable overlap
in range. Although all individuals had normal baseline levels
of thyroxine, 2 of the 32 hypothyroid individuals had initial
TSH levels of ll.l and 13.1/LiU/ml, respectively, at base-
line (the upper limits of normal being 10 /LIU/ml); the others
had TSH levels within the normal rarige. Even without these
two individuals the hypothyroid group had a statistically
elevated TSH of 5.l/LIU/ml (p = 0.05, by one-way analysis
of variance). The results of the basal cholesterol and tri-
glyceride determinations will be discussed later.
Table 2. Baseline Laboratory Variables in Relation to Outcome of Thyroid Hormone Status
During Interval of Follow-up
Reference
(Range) Hypothyroid Hyperthyroid Euthyroid
No. of patients 32 5 62
T4 (JLg/dl ± SO)* 4.5 to 12.0 7.8 ± 1.6 8.8 ± 1.7 7.7 ± 1.8
TSH (JLIU/ml) o to 10
Geometric mean t 5.6 3.0 3.9
Range ± 2 SO 2.2 to 14.1 1.5 to 5.9 1.5 to 10.2
Cholesterol (mg/dl)
Geometric meant 209 186 209
Range ± 2 SO 120 to 363 129 to 269 126 to 347
Triglycerides (mg/dl ± SO)§ 193 ± 79 170 ± 90 182 ± 84
Comparisons among the hypothyroid, hyperthyroid and euthyroid groups: Analysis by one-way analysis of
variance; *p = NS; tp = 0.01 (hypothyroid versus euthyroid groups); :j:p = NS; §p = NS.
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Figure l. Life table analysis of the in-
cidence of thyroid dysfunction in 99 pa-
tients on amiodarone therapy. Shown be-
low are the total number of individuals
evaluated in each period, and the number
of events of hyperthyroidism (*), hypo-
thyroidism (0) and total thyroid dys-
function (0) during each interval: error
bars refer to ::!:: SEM.
Total 1lIyrold Dysfunction
- - - - - - - - Hypoth;;oldJ: ..--
--r--:r--------
Hyperthyroid
18 24 30 36 42 48
Months
64 44 31 22 18 14 5
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8 6 0 0 1 0 0
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Total 99 99 96 83
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Incidence of developing thyroid dysfunction (Fig. 1).
In our patient group, life table analysis suggests that 49%
of the patients receiving amiodarone develop thyroid dys-
function by 36 monthsof follow-up. There was nodifference
in the rate of hypothyroidism or hyperthyroidism in those
who were taking' phenytoin in addition to amiodarone by
life table analysis. The rate of thyroid dysfunction at 36
months was 55 ± 13% (SEM) in patients on phenytoin
treatment and 49 ± 6% in those not taking phenytoin
(p = NS).
Thyroid function tests: predictive value. The data on
thyroid function testing were analyzed to see if any early
changes in thyroid function tests which might be useful to
predict which patient would develop thyroid abnormalities.
Figure 2A shows the mean values of serum thyroxine in the
62 individuals who remained euthyroid. There was an in-
crease in serum T4 which reachedstatistical significance by
the third month and persisted through 3 years. Too few
patients were followed up at 42 and 48 months to maintain
statistical significance, although the trend of increased serum
T4 levels persisted. Figure 28 shows the serum thyroxine
levels in the five individuals who developed hyperthyroid-
ism. Although initial monthly T4 levels in these individuals
were elevated, the levels were within the range of patients
who remained euthyroid. Similarly, in the individuals with
subsequent hypothyroidism (Fig. 28) the serum levels of
thyroxine initially stayed within the range of those who
continued to remain euthyroid. Also, hypothyroidism oc-
curred in one individual as late as 36 months after the start
of amiodarone therapy. There was no correlation of thyroid
function with cumulative dose of amiodarone (the average
cumulativedose in those who developed thyroiddysfunction
...............-............
.... _.......... .... ........_----
-------
Figure 2. Time course of serum levels of
thyroxine (T4 ) in patients on long-term
amiodarone therapy. A. Serum levels of T4
in 62 individuals who remained euthyroid
during evaluation: (A) mean ::!:: SEM:
*p < 0.05: **p < 0.01: NS = not signif-
icant. B. Mean level of T4 (A) and range
::!:: 2 SO (---) of the 62 individuals from A:
(e) the course of five individuals who be-
came hyperthyroid during follow-up: (0)
the course of groups of patients (total 32)
who developed hypothyroidism .
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Figure 3. Time course of serum levels of
cholesterol in 99 patients on chronic amio-
darone therapy. A, Serum levels of cho-
lesterol in 62 individuals who remained eu-
thyroid during evaluation (same as Fig. 2A):
(£) mean ± SEM; *p < 0.05; **p < 0.01;
***p < 0.001; NS = not significant. B,
Mean levels of cholesterol (£) and range
± 2 SO (---) of the 62 individuals from A:
(e) the 5 individuals who became hyper-
thyroid; (0) the course of groups of pa-
tients (total 32) who developed hypo-
thyroidism.
was 120 ± 21 g (SEM), whereas the average dose of those
who remained euthyroid was 182 ± 22 g).
Cholesterol and triglyceride determination. One of
the anticipated findings in primary hypothyroidism was an
increase in serum cholesterol. Unexpectedly, the cholesterol
increased uniformly in all patients (Fig. 3A), The geometric
mean of cholesterol values is shown for the 62 euthyroid
individuals. There was a statistically significant increase in
cholesterol during months 3 through 30 and then a trend
toward increased cholesterol during follow-up when the
number of study patients decreased. As an example, by 6
months the serum cholesterol increased from a mean of 209
mg/dl to 251 mg/dl (p < 0.001 by paired t test, and the
correction of Bonferroni inequality for multiple assessment).
There was a transient, statistically insignificant increase in
serum triglycerides from a baseline level of 182 ± 84 (SEM)
to 231 ± 129 mg/dl by 3 months that returned to a level
of 178 ± 82 mg/dl by 6 months. During the follow-up
period, serum cholesterol remained elevated, whereas tri-
glycerides returned to baseline levels.
Figure 3B demonstrates the change in serum cholesterol
in patients who became hyperthyroid and hypothyroid in a
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Figure 4. Correlation between serum thy-
roxine (T 4 ) and serum reverse (r) T3 (A) and
serum triiodothyronine by radioimmunoas-
say (T3RIA) (B). A random subgroup of 32
individuals was evaluated for reverse T3 and
triiodothyronine (see Methods).
2 • 2 •
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Figure 5. The response of serum
thyroxine (T4 ) levels to replacement
doses of L-thyroxine in individuals with
hypothyroidism due to amiodarone , A.
The effect of thyroid hormonesupple-
mentation on serum T4 levels, Pre re-
fers to the baseline levels of T4 in the
62 individuals who remained euthy-
roid. Post refers to the reference range
of serum T4 values that were found in
the 62 individuals who remained eu-
thyroid while on chronic amiodarone
therapy. Individual pointsare theserum
T4levels obtained at steady-statein the
32 individuals with hypothyroidism
receiving supplementation with L-thy-
roxine. B, The effect of thyroid hor-
mone supplementation on serum thy-
rotropin (TSH) levels. Pre refers to
baseline serum TSH levels and post
refers to TSH levels obtained in the
reference group of 62 euthyroid indi-
viduals on long-term amiodaronether-
apy. Individual points are the serum
TSH levels obtained in the 32 indi-
viduals withhypothyroidism receiving
supplementation with Lthyroxine.
20 A Y = 4.00.ll036. B logY = 1.456 - 0.003.
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manner analogous to that shown in Figure 2B. The change
in cholesterol values of these individuals did not differ from
that in the 62 individuals in the euthyroid comparison group.
Evaluation ~f thyroid functions by reverse T3' Thirty-
two of 'the 99 individuals scheduled for routine follow -up
underwent further thyroid hormone' evaluation with serum
triiodothyronine by radioimmunoassay (T3RIA), reverse T3
and a thyrotropin releasing hormone (TRH) stimulation test.
The baseline characteristics of this subset did not differ from
those of the totai patient group In relation to age, sex, dose
of arniodarone, chemical studies , use of phenytoin and base-
line I~vels of 14 , TSH or cholesterol.
Reverse T3 was not an independent ,variable in these
individuals on long-term medication; it correlated with serum
T4 and varied jn the same direction as T4 (p -< 0.001 ) (Fig .
4A) . Reverse T3 levels were significantly lower in the hy-
pothyroidgroup (n == 16; 43.7 ± 7.6 ng/dl) than in the
euthyroid group (n := ~6 ; 89.2 ± 12.3 ng/dl [p < 0 .01]).
There were no individuals with overt hyperthyroidism when
reverse T3 was tested. There was no correlation of serum
1'4 with T3R!A (Fig. 4B)or of T3RIA with reverse T3 (not
shown). Serum TSH levels followed the expected relation
to serum thyroxine levels , which may be best described as
following an exponential function (data not shown); that is ,
serum TSH increased exponentially with respect to de-
creases in T4 , and decreased toward the lower level of sen-
sitivity of the TSH assay with increases in T4 • TSti followed
a similar exponential relation toward reverse T3; there was
no correlation of TSH with T3RIA. '
Evaluation of thyroid functions by TRH stimulation.
Thirty-two of the 99 patients were evaluated by a TRH
stimulation test (23, 24). The test was minimally useful in
predicting who would develop hypothyroidism in two in-
dividuals who had baseline TSH levels of 11.2 and 11.8,
respectively, and who had " hyperresponsive" rises in TSH
(to levels greater than 30 JLIU/ml at 30 or 60 minutes). Only
one of the five individuals who subsequently developed
hyperthyroidism was evaluated by the TRH test, and the
test did not predict future outcome .
Treatment of hypothyroidism and hyperthyroidism.
We next evaluated the dose of replacement Lthyroxine
necessary for the treatment of patients with hypothyroidism.
Becau se all of these individuals had a predisposition to
arrhythmias and many had concomitant angina , replacement
with thyroid hormone was done cautiously. Figure 5A shows
serum T4 levels before and after institution of amiodarone
therapy in the 62 euthyroid individuals . These reference
range s are used for comparison with the serum T4 obtained
in the 32 hypothyroid patients after L-thyroxine supple-
mentation . Amiodarone increased the mean and upper range
of serum T4 values compared with baseline levels in the 62
euthyroid subjects. The serum level s of T4 in the hypothy-
roidpatients receiving thyroxine supplementation at steady
state (that is, approximately 2 month s after instituting a dose
change in L-thyroxine) showed a statistically significant cor-
relation with the dose of exogenous L-thyroxine. If the
postamiodarone mean of serum T4 levels observed in eu-
thyroid subjects is used as a reference guide for replacement
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of L-thyroxine, then the mean replacement dose of 136
J,Lg/day is not dissimilar from the dose reported previously
for replacement in patients with other causes of hypothy-
roidism (31). If the preamiodarone level of T4 is used as a
guideline, then replacement T4 is 108 J,Lg/day.
Another guide would be to give sufficient replacement
thyroxine to "normalize" TSH (31). Figure 5B shows the
TSH levels before and after amiodarone in the 62 euthyroid
individuals compared with TSH levels obtained after L-
thyroxine supplementation in the 32 individuals with hypo-
thyroidism. There is a borderline significant (p = 0.05)
inverse correlation of TSH levels with the doses of L-thy-
roxine given. The amount of L-thyroxine needed to obtain
a normal geometric mean TSH appears to be excessive (that
is, the dose would be extrapolated to 276 J,Lg/day). Part of
this is an artifact in the loss of sensitivity of the TSH assay
at higher levels of TSH, in that values of TSH are reported
as greater than 50 J,LIU/ml, which skews the resulting linear
regression to a lower slope than would occur if TSH were
reported in absolute values.
Individuals who became clinically hyperthyroid were
treated with methimazole to achieve T4 values within the
reference range; concomitant to amiodarone therapy was
continued because it was believed to be essential for ar-
rhythmia control. These individuals with dual therapy have
been followed up for an average of II months (range 2 to
29). We did not note an exacerbation of arrhythmias during
the intervals before and after the hyperthyroidism was treated.
Discussion
Incidence of thyroid dysfunction. Our observations and
a review of previous studies (1-17) on thyroid function
testing in patients receiving amiodarone suggest it is prob-
able that all patients will demonstrate a change in thyroid
hormone dynamics. Most will manifest alterations in the
conversion of thyroxine to triiodothyronine (T1) as well as
increased levels of reverse T1 as found in the "euthyroid
sick syndrome" (32,33). This alteration in hormone con-
version need not be treated. There is however a sizable
proportion of patients who will develop clinical hypothy-
roidism or hyperthyroidism. It would be important to doc-
ument and treat these individuals with true thyroid dys-
function at an early stage, especially because the thyroid
dysfunction may exacerbate concomitant congestive heart
failure, cardiac arrhythmias or coronary insufficiency. There
are currently no guidelines on how to monitor patients for
thyroid dysfunction or guidelines that help to define the
range of laboratory variables in individuals who remain
euthyroid on long-term amiodarone therapy. We therefore
retrospectively analyzed our data on thyroid hormone func-
tion in a large population (99 patients) over a prolonged
period of amiodarone therapy.
In evaluating individuals receiving amiodarone, the clin-
ical indicators of hypothyroidism such as bradycardia and
weight gain are difficult to separate from the actions of
amiodarone. The symptoms of hyperthyroidism may be
manifested initially as weight loss or arrhythmias. It was
our goal to monitor carefully to prevent hyperthyroidism
and the worsening of arrhythmias. The diagnosis of hypo-
thyroidism and hyperthyroidism therefore rested heavily on
the endocrine laboratory assessment and the appropriate
confirmatory clinical findings. We noted a sizable incidence
of thyroid dysfunction (49%) when individuals were fol-
lowed up for up to 60 months. This contrasted with reported
estimates of 2 to 24%. Several factors might have contrib-
uted to the higher incidence of thyroid dysfunction. First,
we used a life table analysis, which may be a more accurate
representation of the incidence of complications. As an ex-
ample from Figure I, at 12 months we noted approximately
a 30% incidence of thyroid dysfunction by life table analysis
whereas only 9 (9%) of the original 99 developed hypo- or
hyperthyroidism. Also, the age of our patients was 66 ±
10 years (SO), which is older than described in several
previous publications.
Phenytoin, which was used here as a supplementary anti-
arrhythmic agent, has many effects on thyroid hormone
dynamics (27-30). Phenytoin may compete with binding
sites on thyroxine binding globulins, increase the rate of
thyroxine metabolism and affect pituitary release of TSH.
We were unable to find any statistically significant effect
of the combination of amiodarone plus phenytoin compared
with amiodarone alone with regard to the incidence of hypo-
or hyperthyroidism.
We next tried to find clinical indexes or laboratory vari-
ables that might be useful in predicting who would be at
risk for developing hypo- or hyperthyroidism. We were
unable to find clinical features that would predict future
abnormalities when we evaluated age, sex, severity of heart
disease, dose of medication, use of concomitant antiar-
rhythmic agents or other cardiovascular medications. There
was no difference in the baseline level of serum T4 . There
was a statistically significant difference in the baseline pre-
amiodarone level of TSH. Individuals who became hypo-
thyroid had a higher baseline TSH level although all but
two had TSH levels within the euthyroid range by the assays
that were available during the period of this study. It is
possible that these individuals had subclinical hypothyroid-
ism which might be noted by the current highly sensitive
assays for TSH (34,35). There was, however, considerable
overlap between these TSH levels and baseline levels in
patients who remained euthyroid. Other investigators (7,14)
have reported that individuals with a past history of thyroid
disease may be at increased risk of subsequent thyroid dys-
function.
Thyroid dysfunction occurred predominantly within the
first 2 years of amiodarone therapy. There was one indi-
vidual, however, who became hypothyroid only after 3 years
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of therapy. There was no pattern of T4 or TSH serum levels
that could predict which patient would subsequently become
hypo- or hyperthyroid when compared with the pattern and
range of the euthyroid comparison group. The TRH stim-
ulation test was performed in a subset of patients. We were
unable to demonstrate a benefit of routine prospective TRH
testing to predict future thyroid dysfunction in the limited
number of individuals sampled. The TRH test may be help-
ful in a specific situation to clarify the status of an individual
with hyperthyroxinemia, although others (4) have reported
difficulty with interpretation of TRH testing in individuals
receiving amiodarone.
Cholesterol and triglyceride determinations. It has
been stated that one of the mechanisms of amiodarone action
is through selected intracellular myocardial hypothyroidism.
More recent evidence has demonstrated that amiodarone and
its metabolite desethylamiodarone also bind in vitro to pi-
tuitary (17) and liver (21) thyroid hormone receptors, and
may be inhibitors of T4 action.
We noted a striking increase in serum cholesterol in all
individuals treated with amiodarone. Serum cholesterol in-
creased significantly from 209 mg/dl (range 127 to 343) to
251 mg/dl (range 175 to 360). There was a transient increase
in triglycerides (36) with a return to baseline levels by 6
months; the increase in cholesterol was persistent even after
the return of serum triglyceride levels. There are many med-
ications that interfere with cholesterol metabolism. It is pos-
sible that the in vitro observation that amiodarone metab-
olites may be inhibitors of intrahepatic thyroid hormone
receptors has a clinical correlate in hypercholesterolemia.
It would be especially important to know the cause and the
type of the hypercholesterolemia in individuals who are
already predisposed to cardiovascular disease.
Evaluation of thyroid functions by reverse T3' It has
been suggested that reverse T3 is an indicator not only of
amiodarone efficacy, but also of subsequent toxicity (5,6).
The role of reverse T3 in monitoring for amiodarone toxicity
was not prospectively analyzed in this study. We did not
find reverse T3 to be an independent variable for follow-up,
but reverse T3 correlated directly with more conventional
testing of serum thyroxine. Also as discussed by Singh and
Nademanee (6) in relation to the pitfalls of the use of reverse
T3 , there may be variability in the standardization and the
ranges of reverse T3 assays, and there may be alternate
causes of elevations of reverse T3 . From our analysis using
a commercial reverse T3 assay, the test was not an inde-
pendent variable. The role of reverse T3 and T4 with regard
to complications still needs to be clarified (37).
Treatment of hypothyroidism and hyperthyroidism.
There have also not been adequate guidelines for therapy
of thyroid dysfunction during amiodarone administration.
Conventional therapy of hypothyroidism with L-thyroxine
has the goal of obtaining both normal serum T4 and normal
serum TSH levels. Amiodarone interferes with T4 metab-
olism and possible pituitary sensitivity to T4 , with resultant
elevations of TSH. There is also the possibility that one of
the antiarrhythmic properties of amiodarone may be brought
about by causing an intracellular state of hypothyroidism,
by blocking myocardial receptors to thyroid hormone. It
may be self-defeating to "normalize" TSH levels and bring
the patient back to complete intracellular euthyroidism. We
calculated the dose of L-thyroxine used as supplementation
in the hypothyroid individual necessary to bring T4 levels
to the comparable range of euthyroid individuals on long-
term amiodarone therapy. The dose of L-thyroxine required
to approach the mean of the comparison group is 136 ug,
not dissimilar from the dose used in conventional replace-
ment in other causes of hypothyroidism, whereas the dose
of L-thyroxine needed to normalize TSH appears to be ex-
cessive and extrapolates to 276 jLg/day. Interestingly, the
extrapolated theoretical replacement dose of L-thyroxine
that would normalize TSH, is similar to that calculated by
Lambert et al. (4) (250 jLg/day) from analysis of endogenous
thyroxine production rates in individuals receiving amio-
darone. It has been our policy to give small supplemental
doses of L-thyroxine to achieve serum T4 levels within the
range of the comparison euthyroid amiodarone group, rather
than requiring that TSH values be normal.
Many individuals with malignant arrhythmias or coro-
nary insufficiency might not tolerate hyperthyroidism. We
have therefore made our adjustments cautiously using clin-
ical evaluation and ambulatory electrocardiographic moni-
toring as a supplement to conventional T4 and TSH labo-
ratory values. We also did not note exacerbationof arrhythmias
or congestive heart failure in those who developed thyroid
dysfunction possibly because of the close clinical follow-
up and treatment and prompt correction of the abnormal
thyroid dynamics.
Conclusions. Amiodarone may cause abnormalities of
thyroid function testing in all individuals. A sizeable pro-
portion will have clinically significant hyper- or hypothy-
roidism. Individuals with baseline elevated TSH may be at
a greater risk of hypothyroidism and highly sensitive TSH
assays may be beneficial in evaluation for subclinical hypo-
or hyperthyroidism. There were no clinical features that
were useful to predict who would develop thyroid dysfunc-
tion. Individuals might first develop thyroid dysfunction as
long as 3 years after the onset of amiodarone therapy. We
therefore recommend that thyroid function tests be per-
formed at 3 to 4 month intervals during long-term manage-
ment in order to recognize and treat thyroid dysfunction at
an early stage. In individuals who develop hypothyroidism,
we have used cautious titration of exogenous L-thyroxine
to "normalize" serum Tz levels, whereas we have not used
the "supraphysiologic" doses of L-thyroxine that would be
necessary to normalize TSH. Serum cholesterol values in-
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creased in all patients treated with amiodarone. The type
and cause of the hypercholesterolemia need to be addressed
in individuals with underlying heart disease.
We thank Charlye Gross , RN, who assisted in the data acquisition and
Bernard Chairman. MD, Harold Kennedy, MD, Mike Perry . MD. and
Alan Silverberg, MD for review of the manuscript.
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